HealthCo Healthcare and Wellness REIT (ASX: HCW) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

HealthCo Healthcare and Wellness REIT Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $633.93 million
P/E Ratio 93.44
Dividend Yield 7.11%
Shares Outstanding 561.00 million
Earnings per share 0.012
Dividend per share 0.08
Year To Date Return -16.33%
Earnings Yield 1.07%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • HealthCo Healthcare and Wellness REIT (ASX: HCW)
    Latest News

    Person handing out $50 notes, symbolising ex-dividend date.
    Dividend Investing

    Buy these ASX dividend stocks with 7%+ yields

    Analysts expect these stocks to make it rain dividends for their shareholders.

    Read more »

    Middle age caucasian man smiling confident drinking coffee at home.
    Dividend Investing

    Should you buy BHP and these ASX dividend shares?

    What are analysts saying about these income stocks?

    Read more »

    Happy man holding Australian dollar notes, representing dividends.
    Dividend Investing

    3 ASX dividend stocks with 7%+ yields to buy now

    Analysts say these buy-rated shares will provide big dividend yields.

    Read more »

    Woman relaxing on her phone on her couch, symbolising passive income.
    Dividend Investing

    3 ASX dividend shares to buy with 6%+ yields

    Analysts are feeling bullish about these dividend-payers.

    Read more »

    Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
    Dividend Investing

    4 ASX dividend shares to buy next week

    Brokers think income investors should be buying these stocks.

    Read more »

    Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
    Dividend Investing

    5 ASX dividend stocks to buy with 6%+ yields

    Brokers have put buy ratings on these high-yield stocks.

    Read more »

    Happy young woman saving money in a piggy bank.
    Dividend Investing

    Buy these ASX dividend stocks for 5%+ yields

    Analysts are forecasting some big dividend yields from these stocks.

    Read more »

    Young woman using computer laptop smiling in love showing heart symbol and shape with hands. as she switches from a big telco to Aussie Broadband which is capturing more market share
    Dividend Investing

    Why brokers love these ASX dividend stocks

    They have good things to say about these income options.

    Read more »

    Man holding out Australian dollar notes, symbolising dividends.
    Dividend Investing

    Buy these ASX dividend stocks for 5% to 7% yields

    Analysts say these are top options for income investors this week.

    Read more »

    Two smiling work colleagues discuss an investment or business plan at their office.
    Broker Notes

    Morgans says these 4 ASX 300 stocks are post-results buys

    The broker was pleased with these results. Here's what you need to know.

    Read more »

    Man holding out Australian dollar notes, symbolising dividends.
    Dividend Investing

    These 5%+ ASX dividend shares pay cash every quarter

    Analysts are tipping these stocks that pay quarterly dividends as buys.

    Read more »

    Three people in a corporate office pour over a tablet, ready to invest.
    Broker Notes

    7 ASX shares elevated to 'strong buy' ratings in July

    CommSec data shows these stocks now have the strongest possible consensus buy recommendation.

    Read more »

    Frequently Asked Questions

    Yes, HealthCo Healthcare and Wellness REIT has historically paid four unfranked unitholder distributions a year.

    HealthCo Healthcare and Wellness REIT generally pays its unitholder distributions in February, May, August, and November.

    HealthCo Healthcare and Wellness REIT listed on the ASX on 6 September 2021.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    27 Sep 2024 $0.0210 0.00% Interim 22 Nov 2024
    27 Jun 2024 $0.0200 0.00% Final 22 Aug 2024
    27 Mar 2024 $0.0200 0.00% Interim 22 May 2024
    28 Dec 2023 $0.0200 0.00% Interim 21 Feb 2024
    28 Sep 2023 $0.0200 0.00% Interim 29 Nov 2023
    29 Jun 2023 $0.0200 0.00% Final 30 Aug 2023
    01 May 2023 $0.0188 0.00% Interim 23 Jun 2023
    29 Dec 2022 $0.0188 0.00% Interim 24 Feb 2023
    29 Sep 2022 $0.0188 0.00% Interim 25 Nov 2022
    29 Jun 2022 $0.0225 0.00% Final 22 Aug 2022
    30 Mar 2022 $0.0225 0.00% Interim 20 May 2022
    30 Dec 2021 $0.0300 0.00% Interim 25 Feb 2022

    HCW ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About HealthCo Healthcare and Wellness REIT

    HealthCo Healthcare and Wellness REIT (ASX: HCW) owns and manages a portfolio of commercial health and wellness real estate assets. The REIT is under the umbrella of HMC Capital (ASX: HMC), a listed asset manager that invests on behalf of individuals, large institutions, and super funds.

    HealthCo Healthcare and Wellness REIT holds a $1.6 billion portfolio of 36 properties including hospitals, aged care, childcare, life sciences and research facilities as well as primary care and wellness assets. The portfolio covers Queensland, New South Wales, Victoria, and Western Australia with a weighted average lease expiry (WALE) of 12 years. 

    HCW Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Nov 2024 $1.13 $-0.01 -0.88% 752,514 $1.15 $1.15 $1.12
    19 Nov 2024 $1.14 $0.01 0.88% 1,113,174 $1.15 $1.15 $1.13
    18 Nov 2024 $1.13 $0.01 0.89% 1,130,526 $1.12 $1.14 $1.11
    15 Nov 2024 $1.12 $0.00 0.00% 1,189,323 $1.12 $1.14 $1.11
    14 Nov 2024 $1.13 $0.00 0.00% 764,353 $1.14 $1.14 $1.12
    13 Nov 2024 $1.12 $0.00 0.00% 776,332 $1.14 $1.14 $1.12
    12 Nov 2024 $1.13 $0.00 0.00% 647,677 $1.13 $1.14 $1.12
    11 Nov 2024 $1.12 $0.01 0.90% 783,584 $1.12 $1.13 $1.12
    08 Nov 2024 $1.12 $0.00 0.00% 1,173,913 $1.12 $1.13 $1.10
    07 Nov 2024 $1.11 $-0.02 -1.77% 850,542 $1.15 $1.15 $1.11
    06 Nov 2024 $1.13 $0.00 0.00% 516,608 $1.13 $1.13 $1.11
    05 Nov 2024 $1.13 $0.00 0.00% 312,173 $1.13 $1.13 $1.12
    04 Nov 2024 $1.13 $-0.01 -0.88% 450,875 $1.14 $1.14 $1.12
    01 Nov 2024 $1.14 $-0.01 -0.87% 570,779 $1.16 $1.16 $1.13
    31 Oct 2024 $1.15 $0.00 0.00% 580,755 $1.15 $1.16 $1.14
    30 Oct 2024 $1.15 $0.00 0.00% 602,785 $1.15 $1.17 $1.13
    29 Oct 2024 $1.15 $-0.01 -0.86% 1,335,291 $1.16 $1.17 $1.14
    28 Oct 2024 $1.16 $-0.01 -0.85% 854,898 $1.17 $1.18 $1.16
    25 Oct 2024 $1.17 $0.01 0.86% 759,027 $1.17 $1.18 $1.17
    24 Oct 2024 $1.16 $0.00 0.00% 1,165,510 $1.18 $1.18 $1.16
    23 Oct 2024 $1.16 $0.00 0.00% 665,882 $1.17 $1.18 $1.16
    22 Oct 2024 $1.16 $-0.01 -0.85% 1,355,911 $1.17 $1.18 $1.15

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Sep 2024 Kelly O'Dwyer Buy 12,824 $15,645
    As advised by the company. Tranche 2 of 2 of the acquisition of units
    pursuant to participation in the FY24
    voluntary non-executive director unit
    acquisition
    02 Sep 2024 Joseph Carrozzi Buy 12,513 $15,265
    As advised by the company. Tranche 2 of 2 of the acquisition of units
    pursuant to participation in the FY24
    voluntary non-executive director unit
    acquisition
    02 Sep 2024 Natalie Meyenn Buy 15,310 $18,678
    As advised by the company. Tranche 2 of 2 of the acquisition of units
    pursuant to participation in the FY24
    voluntary non-executive director unit
    acquisition
    16 May 2024 Christopher Roberts Buy 85,490 $100,878
    On-market trade.
    16 May 2024 Christopher Roberts Sell 9,636 $11,322
    On-market trade.
    18 Mar 2024 David Di Pilla Sell 37,990 $100
    As advised by the company. Disposal of further units by Home Consortium
    Developments Pty Ltd ACN 635 859 700 for nominal
    consideration of AUD$100 pursuant to a selective
    buyback which was approved by HCW unitholders at an
    EGM on 24 July 2023.
    27 Feb 2024 Kelly O'Dwyer Buy 11,705 $15,567
    As advised by the company. Tranche 1 of 2 of the acquisition of units
    pursuant to participation in the FY24
    voluntary non-executive director unit
    acquisition arrangement as summarised in
    HCW's Product Disclosure Statement dated 2
    August 2021.
    27 Feb 2024 Joseph Carrozzi Buy 10,807 $14,373
    As advised by the company. Tranche 1 of 2 of the acquisition of units
    pursuant to participation in the FY24
    voluntary non-executive director unit
    acquisition arrangement as summarised in
    HCW's Product Disclosure Statement dated 2
    August 2021.
    27 Feb 2024 Natalie Meyenn Buy 13,998 $18,617
    As advised by the company. Tranche 1 of 2 of the acquisition of units
    pursuant to participation in the FY24
    voluntary non-executive director unit
    acquisition arrangement as summarised in
    HCW's Product Disclosure Statement dated 2
    August 2021.
    16 Feb 2024 David Di Pilla Buy 31,912,867 $42,603,677
    On-market trade.
    21 Dec 2023 David Di Pilla Sell 179,175 $100
    As advised by the company. Disposal of further units by Home Consortium
    Developments Pty Ltd (ACN 635 859 700) for
    nominal consideration of AUD$100 pursuant
    to a selective buyback.
    04 Dec 2023 Christopher Roberts Buy 12,404 $17,551
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units
    under the capital raising announced by HCW
    on 30 March 2023.
    04 Dec 2023 Stephanie Lai Buy 181 $256
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units
    under the capital raising announced by HCW
    on 30 March 2023.
    04 Dec 2023 Stephanie Lai Buy 3,082 $4,361
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units
    under the capital raising announced by HCW
    on 30 March 2023.
    04 Dec 2023 David Di Pilla Buy 9,397 $13,296
    As advised by the company. Acquisition of fully paid ordinary
    units for nil consideration pursuant to an
    entitlement to bonus units under the capital
    raising announced by HCW on 30 March 2023.
    04 Dec 2023 David Di Pilla Sell 3,268,896 $100
    As advised by the company.
    04 Dec 2023 Kelly O'Dwyer Buy 511 $63,329
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units
    under the capital raising announced by HCW
    on 30 March 2023.
    04 Dec 2023 Kelly O'Dwyer Buy 469 $663
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units
    under the capital raising announced by HCW
    on 30 March 2023.
    04 Dec 2023 Joseph Carrozzi Buy 4,021 $5,689
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units
    under the capital raising announced by HCW
    on 30 March 2023.
    04 Dec 2023 Natalie Meyenn Buy 745 $1,054
    As advised by the company. Acquisition of fully paid ordinary units
    pursuant to an entitlement to bonus units under
    the capital raising announced by HCW on 30
    March 2023.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Christopher Graham Roberts Non-Executive Director Aug 2021
    Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board and a Non-Executive Director of Sigma Healthcare Limited, Clarity Pharmaceuticals Limited, HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. Chris was a former Chair of Research Australia from 2004 to 2010.
    Ms Stephanie Mei-Nga Lai Non-Executive Director Aug 2021
    Ms Lai e has over 25 years of experience, is a Chartered Accountant and is a former Transaction Services partner of Deloitte and KPMG. She has experience providing due diligence and advisory services, including forecast reviews to listed entities, sovereign wealth funds, wealth managers and private equity. She is Chair of Risk Committee.
    Mr David Anthony Di Pilla Non-Executive Director Jul 2021
    Mr Pilla has over 30 years of experience in investment banking, strategic advisory and consulting, and corporate leadership as a Director and CEO. During his 20 years of investment banking career, David was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australia's landmark transactions across corporate M&A, Equity & Debt Capital Markets. Prior to his time at UBS, David reached the position of Vice President, Investment Banking at JP Morgan.
    Hon Kelly Megan O'Dwyer Non-Executive Director Aug 2021
    Ms O'Dwyer previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations, Minister for Revenue and Financial Services, Minister for Small Business, and Assistant Treasurer. She also served on the Cabinet's Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women, as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, Kelly worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking.
    Mr Joseph Carrozzi Non-Executive ChairmanNon-Executive Director Aug 2021
    Mr Carrozzi has over 25 years of experience as a managing partner in the Big 4 professional services firms. He has experience in infrastructure, health and medical research as well as sectors which are highly regulated. He is currently the Chair of the Centenary Institute for Medical Research, the Angus Knight Group, as well as a board member of the National Intermodal Corporation, the NSW Business Chamber, Football Australia, Aurrum Pty Ltd and ServiceGen Pty Ltd. Joseph was formerly Chair of the Sydney Harbour Federation Trust and Deputy Chair of the NSW Institute of Sport. He is also a member of Risk Committee.
    Ms Natalie Jane Meyenn Non-Executive Director Aug 2021
    Ms Meyenn has over 25 years of experience in financial services and investing globally. She was Head and Chair of the Investment Committee for MLC Private Equity and is currently co-founder of an agriculture investment firm and adviser and/or investment committee member to a small number of asset management, private equity and non-profits including New Energy Nexus and Yielco Investments. She worked in investment banking (M&A, capital markets and public finance) for Goldman Sachs and Bear Stearns in New York and Sydney and for the World Bank on micro-credit, project finance and climate impact mitigation in Asia, Africa and the Pacific Islands. She is also a member of Risk Committee.
    Mr Andrew Selim Company SecretaryGeneral Counsel
    -
    Andrew Selim Company SecretaryGeneral Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Home Consortium Developments Limited 89,871,409 16.02%
    J P Morgan Nominees Australia Pty Limited 80,211,627 14.30%
    HSBC Custody Nominees (Australia) Limited 76,429,553 13.62%
    Citicorp Nominees Pty Limited 36,237,475 6.46%
    Home Consortium Limited 35,034,393 6.24%
    BNP Paribas Noms Pty Ltd 29,916,793 5.33%
    Netwealth Investments Limited (Wrap Services A/C) 7,033,080 1.25%
    National Nominees Limited 5,140,105 0.92%
    BNP Paribas Nominees Pty Ltd (HUB24 Custodial Serv Ltd) 4,858,930 0.87%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,444,729 0.79%
    HSBC Custody Nominees (Australia) Limited A/C 2 3,273,968 0.58%
    HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) 2,540,200 0.45%
    Netwealth Investments Limited (Super Services A/C) 2,284,185 0.41%
    BNP Paribas Nominees Pty Ltd (Pitcher Partners) 2,282,189 0.41%
    Goat Properties Pty Ltd 1,986,390 0.35%
    Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 1,609,218 0.29%
    Sword Excalibur Equities Pty Ltd (Sword Excalibur EQ 2 A/C) 1,597,222 0.28%
    Glengallan Investments Pty Ltd 1,188,249 0.21%
    Premium Capital (Aust) Pty Ltd 1,082,000 0.19%
    Seymour Group Pty Ltd 1,078,000 0.19%

    Profile

    since

    Note